Tubulin inhibitors by themselves can limit tumor growth, and they can be particularly effective when conjugated to monoclonal antibodies that target them to tumors. Two such conjugates, trastuzumab emtansine and brentuximab vedotin, have been approved by the FDA. However, many cancers can develop resistance to such inhibitors, highlighting the need for next-generation compounds.